GSK

Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer.

Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.

GSK is expected to report a year-over-year earnings decline of 5.4% to $1.40 per share for Q3 2026, despite revenues rising 2.4% to $11.8 billion. With a negative Earnings ESP of -4.56% and Zacks Rank #4, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten estimates in recent quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.

HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights (excluding Greater China and Taiwan) to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. HUTCHMED will receive $110 million upfront and up to $1.185 billion in milestone payments, plus tiered royalties. HUTCHMED remains responsible for global Phase I development.

GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years.

The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.

GSK received FDA approval for Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The AZUR-1 trial showed 68% of patients achieved sustained clinical complete responses at 12 months without surgery, with no disease recurrences reported among responders after median follow-up of over 2 years. The approval could help eligible patients avoid chemotherapy, radiation, and surgery.

The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.

GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.

HUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.

Alnylam Pharmaceuticals is expected to report Q3 2026 earnings on October 29, with consensus EPS of $2.19 (down 24.5% YoY) and revenues of $1.45 billion (up 16% YoY). The company has a positive Earnings ESP of +0.84% combined with a Zacks Rank #3, suggesting a likely earnings beat. However, the company missed estimates in the last quarter by 10.24%.

The MASH (Metabolic Dysfunction-Associated Steatohepatitis) market is rapidly expanding with over 180 companies developing 200+ pipeline therapies. Two drugs have been approved: REZDIFFRA (resmetirom) by Madrigal Pharmaceuticals and LIPAGLYN/BILYPSA (saroglitazar magnesium) by Zydus Lifesciences. The competitive landscape is intensifying with emerging mechanisms of action including FGF21 replacements, GLP-1 receptor agonists, and dual glucagon/GLP-1 agonists, with approximately 5+ drugs in late-stage development and 100+ in mid and early stages.

D-Wave Quantum has surged over 1,000% in two years, but the article cautions that much of this rally is driven by hype rather than operational results. While the company shows strong booking growth (1,120% YoY), revenue remains flat at $3.1M and operating losses doubled to $53.3M. With a P/S ratio of 362, the stock is priced for perfection, and analysts suggest waiting for a lower entry point despite the transformational potential of quantum computing technology.

The article identifies three dividend stocks with strong fundamentals and resilient business models that are likely to continue raising payouts through economic downturns: WD-40 Company with 40 years of uninterrupted dividends backed by an iconic product with minimal competition, Energizer Holdings yielding 5.9% with essential consumer products, and Haleon with a conservative payout policy and health brands used by over a billion consumers worldwide.

Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline.

Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Hatteras Venture Partners appointed Sir Andrew Witty as Chairman and Dr. Ned Sharpless as Managing Director of Hatteras Discovery Innovation. The firm announced the first closing of Hatteras Opportunity Fund II targeting $100 million, bringing total capital under management to over $1 billion. The new Discovery strategy aims to replicate the success of the original 2012 initiative that seeded 11 companies and contributed to two FDA-approved medicines.